Certain lesions in the spinal cords of people with multiple sclerosis (MS) show damage to nerve fibers despite having normal myelin, according to a study done on postmortem samples using powerful MRI scans paired with detailed tissue analyses. The identification of these lesions “provides a novel opportunity to detect…
News
The National Multiple Sclerosis Society is investing more than $18 million in new grants and fellowships to support multiple sclerosis (MS) research aligned with its Pathways to Cures initiative, which seeks to stop MS progression, restore lost function, and prevent the disease. This latest round of funding…
May marks Multiple Sclerosis Awareness Month in Canada, and people across the country can take part in advocacy and fundraising activities to support the multiple sclerosis (MS) community. MS Canada‘s nationwide campaign urges people to participate in MS walks, parlay a hobby or passion into a fundraiser, share…
Wider rims of immune cells surrounding multiple sclerosis (MS) lesions in the brain and spinal cord are associated with faster disease progression, a new study shows. Monitoring this type of lesion may help track MS disease progression and measure how the disease is responding to treatment, and the…
Vidofludimus calcium, an experimental oral therapy from Immunic Therapeutics, reduced the risk of confirmed disability worsening and slowed brain shrinkage in people with progressive forms of multiple sclerosis (MS). That’s according to top-line data from CALLIPER (NCT05054140), a Phase 2 clinical trial testing a daily dose of…
The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14 to bring together members of the multiple sclerosis (MS) community, celebrate achievements, and raise support for the organization’s free programs and services. The fundraising event will take place at…
Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test, which uses data from blood biomarkers to assess multiple sclerosis (MS) disease activity, is now available across all 50 U.S. states to help guide clinicians’ decisions about care. Octave said the test received certification from the New York State Clinical…
The thyroid hormone thyroxine, or FT4, may play an indirect role in the development of multiple sclerosis (MS), which seems to be mediated by certain immune cells, a study suggests. “Future investigations should explore how these immune cells modulate MS onset and progression in the context of thyroid…
A new machine learning tool, a form of artificial intelligence (AI), may accurately detect the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) — and may be able to do so even earlier than clinicians can — a new study showed. According to the…
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly change their risk of developing cardiovascular disease, a small study showed. Individual cardiovascular risk factors and 10-year risk estimation tools showed no significant changes…
The Patient-Centered Outcomes Research Institute (PCORI) has awarded the Cleveland Clinic $6.7 million to identify optimal treatment strategies for people with relapsing-remitting multiple sclerosis (RRMS). The funds will support the extension study of the multicenter DELIVER-MS (NCT03535298) clinical trial. The study is comparing two MS treatment approaches…
Bionxt Solutions is getting ready to launch a pilot clinical trial to test BNT23001, its sublingual (under-the-tongue) version of cladribine to treat multiple sclerosis (MS). The treatment would be an alternative to Mavenclad, the approved tablet form of cladribine. Bionxt‘s thin-film formulation quickly dissolves under the tongue,…
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and Wellness Forum for MS, presented by Yoga Moves MS — a U.S. program aiming to improve quality of life for those with neuromuscular conditions — on May 21 in Michigan…
Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination, cognitive function, and emotional regulation, from damage in people with multiple sclerosis (MS), a study suggested. Data from the clinical studies that supported Ocrevus’ approval…
New diagnostic criteria and biomarkers, how to manage MS in older patients and children, and vaccine recommendations are among topics covered in a new set of guidelines for best practices in multiple sclerosis (MS) care. The Consortium of Multiple Sclerosis Centers, a network of more than 15,000 clinicians…
Exercise programs that are culturally tailored to Hispanics with multiple sclerosis (MS) may help these patients engage in regular physical activity, according to an interview-based study. The patients surveyed also say they prefer exercise that’s performed three to five days per week, and led by a coach in community…
The healthcare costs of secondary progressive multiple sclerosis (SPMS) are high, according to a real-world study in Spain, and higher still for younger patients and those with severe disability who cannot walk unaided, even for short distances. On average, yearly costs for one patient amount to more than €41,000…
The risk of multiple sclerosis (MS) is significantly higher in people who carry a variant of the HLA gene called HLA-E*01:01 and have a history of infectious mononucleosis (mono), the manifestation of an Epstein-Barr virus (EBV) infection, according to a study based on U.K. Biobank data. The higher…
An online training program for managing memory and cognitive difficulties may help people with multiple sclerosis (MS), a study suggests. The program, delivered entirely through virtual sessions, taught participants practical strategies to boost memory then guided them about using the techniques in real-world situations, such as organizing errands, planning…
Assessing multiple sclerosis (MS) disease activity using Octave Bioscience’s MS Disease Activity (MSDA) blood biomarker test can help guide clinicians’ decisions about care, a study showed. “Our goal is to empower both providers and patients with precision tools that transform MS care,” Doug Biehn, CEO of Octave, said…
One year of Tysabri (natalizumab) treatment improves working ability among people with relapsing-remitting multiple sclerosis (RRMS), according to new data from TITAN, an observational study by researchers in France that assessed the impact of the infusion therapy. Use of the approved therapy resulted in improvements across several parameters:…
Some exercises are better than others at easing certain problems associated with balance in people with multiple sclerosis (MS), and the most effective type may depend on a patient’s specific issue, a small study suggested. The findings “provide valuable insights into the long-term effects of these exercises,” the researchers…
Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much lower cost to patients — as the approved therapy Ocrevus (ocrelizumab) at managing relapsing forms of the disease, a new study from Egypt suggests. The study’s results showed that the…
People with multiple sclerosis (MS) who live in rural areas are 17% less likely to receive disease-modifying therapies (DMTs) than those in urban regions, a study involving people from the Canadian province of Alberta suggested. The likelihood was lower when considering therapies that are highly effective at controlling…
Biostate AI is partnering with the nonprofit Accelerated Cure Project (ACP) to develop a series of artificial intelligence (AI) models that can predict multiple sclerosis (MS) progression and how patients may respond to treatment. As part of the partnership, Biostate AI will use its high-throughput technology to…
Medicaid coverage for people with multiple sclerosis (MS) in the U.S. is associated with worse disease outcomes — including more clinical relapses and greater disability progression — compared with private insurance, according to a new study that investigated the impact of insurance type and socioeconomic factors on patient care. In…
A single 600 mg dose of Briumvi (ublituximab-xiiy) — instead of the approved 150 mg initial dose plus a 450 mg dose two weeks later — was well tolerated by adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from the ENHANCE Phase…
From 2019 to 2023, people with relapsing-remitting multiple sclerosis (RRMS) in France on treatment with Tysabri (natalizumab) adopted more at-home dosing and longer periods between doses, according to a review by researchers of the French national hospital database. An increasing use of the therapy during…
Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy, in people with progressive forms of multiple sclerosis (MS) in clinical testing. That’s according to data from two investigator-initiated Phase 1 trials, which enrolled individuals with secondary progressive…
A pair of scientists have been awarded a 2025 Breakthrough Prize in Life Sciences for their work uncovering factors that give rise to multiple sclerosis (MS), paving the way for new therapeutic developments. Sometimes referred to as the “Oscars of Science,” Breakthrough Prizes are given each year to…